Alteogen Inc.
196170
Rang în acțiuni
#1844
ALTEOGEN Inc., a bio company, focuses on developing long-acting biobetters,... ALTEOGEN Inc., a bio company, focuses on developing long-acting biobetters, proprietary antibody-drug conjugates, and antibody biosimilars. The company develops ALT-P1, a long-acting human growth hormone that is in the Phase IIa clinical trial; and ALT-Q2, a long-acting active form of coagulation factor VII for the treatment of hemophilia based on its NexP technology. It is also involved in the development of ALT-P7, a targeted breast/gastric cancer drug that is in the Phase I clinical trial; ALT-Q5, an antibody-drug conjugate (ADC) for the treatment of ovarian cancer based on its NexMab ADC technology; and ALT-LS2, a SC (subcutaneous) formulation of trastuzuamb for the treatment of breast and gastric cancer. The company has a strategic alliance with Kissei Pharmaceutical for the development of ALT-L9, a biosimilar of Eylea (Aflibercept) which is currently under Phase 1 trial; Cristalia for the development of ALT-L2, a biosimilar of Herceptin (Trastuzumab), a monoclonal antibody for the treatment of breast cancer, which is in the Phase II clinical trial; and Biogen Inc. to develop subcutaneous (SC) formulations of biologics utilizing ALT-B4. ALTEOGEN Inc. was founded in 2008 and is headquartered in Daejeon, South Korea.
Preț acțiune
$165.61
Capitalizare de piață
$11.53B
Schimbare (1 zi)
4.13%
Schimbare (1 an)
-46.48%
Țară
KR
Tranzacționează Alteogen Inc. (196170)
Categorie
Healthcare
Raport P/B pentru Alteogen Inc. (196170)
Raport P/B la data de October 2026 TTM: 28.84
Conform celor mai recente rapoarte financiare și prețului acțiunilor Alteogen Inc., raportul P/B actual (TTM) este 28.84. La sfârșitul anului 2023, compania avea un P/B de 31.91.
Istoricul raportului P/B pentru Alteogen Inc. din 2012 până în 2026
Raport P/B la sfârșitul fiecărui an
| An | Raport P/B | Schimbă |
|---|---|---|
| 2026 (TTM) | 28.84 | -52.00% |
| 2024 | 60.09 | 88.28% |
| 2023 | 31.91 | 133.77% |
| 2022 | 13.65 | -52.14% |
| 2021 | 28.52 | -65.29% |
| 2020 | 82.17 | 542.18% |
| 2019 | 12.80 | 118.43% |
| 2018 | 5.86 | -19.72% |
| 2017 | 7.30 | 69.68% |
| 2016 | 4.30 | -28.85% |
| 2015 | 6.04 | 101.09% |
| 2014 | 3.01 | -68.20% |
| 2013 | 9.45 | -27.57% |
| 2012 | 13.05 | 0.00% |
Raport P/B pentru companii similare sau competitoare
| Companie | Raport P/B | Diferență raport P/B | Țara |
|---|---|---|---|
| 6.251 | -78.33% |
US
|
|
| 13.2547 | -54.05% |
US
|
|
| 4.208 | -85.41% |
AU
|
|
| - | - |
CH
|
|
| 6.1824 | -78.57% |
NL
|
